Open Access

Diagnostic performance of the urinary canine calgranulins in dogs with lower urinary or urogenital tract carcinoma

  • Romy M. Heilmann1, 2Email author,
  • Elizabeth A. McNiel3, 4,
  • Niels Grützner5, 2,
  • David J. Lanerie2,
  • Jan S. Suchodolski2 and
  • Jörg M. Steiner2
BMC Veterinary ResearchBMC series – open, inclusive and trusted201713:112

https://doi.org/10.1186/s12917-017-1032-5

Received: 20 December 2016

Accepted: 17 April 2017

Published: 21 April 2017

Abstract

Background

Onset of canine transitional cell carcinoma (TCC) and prostatic carcinoma (PCA) is usually insidious with dogs presenting at an advanced stage of the disease. A biomarker that can facilitate early detection of TCC/PCA and improve patient survival would be useful. S100A8/A9 (calgranulin A/B or calprotectin) and S100A12 (calgranulin C) are expressed by cells of the innate immune system and are associated with several inflammatory disorders. S100A8/A9 is also expressed by epithelial cells after malignant transformation and is involved in the regulation of cell proliferation and metastasis. S100A8/A9 is up-regulated in human PCA and TCC, whereas the results for S100A12 have been ambiguous. Also, the urine S100A8/A9-to-S100A12 ratio (uCalR) may have potential as a marker for canine TCC/PCA. Aim of the study was to evaluate the diagnostic accuracy of the urinary S100/calgranulins to detect TCC/PCA in dogs by using data and urine samples from 164 dogs with TCC/PCA, non-neoplastic urinary tract disease, other neoplasms, or urinary tract infections, and 75 healthy controls (nested case-control study). Urine S100A8/A9 and S100A12 (measured by species-specific radioimmunoassays and normalized against urine specific gravity [S100A8/A9USG; S100A12USG], urine creatinine concentration, and urine protein concentration and the uCalR were compared among the groups of dogs.

Results

S100A8/A9USG had the highest sensitivity (96%) and specificity (66%) to detect TCC/PCA, with specificity reaching 75% after excluding dogs with a urinary tract infection. The uCalR best distinguished dogs with TCC/PCA from dogs with a urinary tract infection (sensitivity: 91%, specificity: 60%). Using a S100A8/A9USG ≥ 109.9 to screen dogs ≥6 years of age for TCC/PCA yielded a negative predictive value of 100%.

Conclusions

S100A8/A9USG and uCalR may have utility for diagnosing TCC/PCA in dogs, and S100A8/A9USG may be a good screening test for canine TCC/PCA.

Keywords

Biomarker Calprotectin Diagnostic accuracy S100A8/A9 S100A12 Transitional cell carcinoma

Background

Transitional cell carcinoma (TCC) is the most common naturally occurring lower urinary tract malignancy in dogs affecting a number of canine patients [13]. Several predisposing factors (including the use of certain drugs, chemicals, or preventive medications, breed, gender, and diet) have been evaluated (reviewed by Fulkerson et al. [3]). Despite many advances in the management of dogs with TCC or prostatic carcinoma (PCA), early detection of these neoplasms is rare, and their onset is usually insidious with dogs presenting at an advanced stage of the disease (20–40% with metastasis) [14]. Thus, as with any cancer, a biomarker that can facilitate early detection of TCC/PCA (i.e., cancer screening) and improve patient survival would be a useful tool in clinical practice.

Urinary cytology as a test for TCC/PCA has been demonstrated to have a low sensitivity and specificity [3, 5]. The veterinary bladder tumor antigen (V-BTA) test has been evaluated as a non-invasive screening tool for TCC in dogs and is currently the biomarker with the best diagnostic accuracy for non-invasive TCC diagnosis, but this test was shown to have a high false-positive rate (12–65%) [69]. Concentrations of urinary basic fibroblast growth factor was also increased in dogs with bladder cancer and to some extent discriminated dogs with TCC from dogs with a urinary tract infection (UTI) [10], but sensitivity and specificity of urinary basic fibroblast growth factor have not been reported in a larger population of dogs. A recent urine metabolomics study identified a metabolite signature that could discriminate dogs with TCC from healthy control dogs with a sensitivity of 86% and a specificity of 78% [11], and a mass spectrometry analysis of canine urine samples identified a multiplex biomarker model predicting the presence of TCC with 90% diagnostic accuracy [12]. However, the utility of these models as either a screening tool or a diagnostic test for canine TCC has not been evaluated to date.

S100A8/A9 (calgranulin A/B) and S100A12 (calgranulin C) are members of the S100/calgranulin family of Ca2+-binding proteins, and both members are expressed by cells of the innate immune response [13]. Aside from its association with several inflammatory diseases [13, 14], the S100A8/A9 protein complex (also referred to as calprotectin) has been shown to be expressed by epithelial cells after malignant transformation [1518] and to be involved in the regulation of cell proliferation [19] and metastasis [20, 21]. In humans, both S100A9 and S100A8 were found to be up-regulated in PCA and TCC [2230], whereas studies on the expression of S100A12 in TCC/PCA have yielded ambiguous results [31, 32]. However, S100A12 has not been investigated extensively in cancer patients.

Similar to human urothelial carcinoma, the S100A8/A9 gene has been shown to harbour an increased frequency of copy number gains in canine urothelial carcinoma [33], and pilot data by our group suggested that the urinary concentration of S100/calgranulins, particularly the S100A8/A9-to-S100A12 ratio (uCalR), may have potential as a diagnostic biomarker for TCC/PCA in dogs [34]. Thus, further evaluation of the urinary S100/calgranulins and uCalR in dogs is needed to determine their specificity for the diagnosis of TCC/PCA. This retrospective case-control study investigated urine S100A8/A9 and S100A12 concentrations as well as the uCalR in dogs with TCC/PCA (treated or treatment-naïve), dogs with other diseases of the urinary tract, dogs with neoplastic diseases not involving the urinary tract, and healthy control dogs. We hypothesized (1) that the concentration of S100/calgranulins in urine specimens is a useful screening test for TCC/PCA and (2) that the uCalR can distinguish dogs with TCC/PCA and UTI with high diagnostic accuracy.

Methods

Sampling population

A nested case-control study design was used. Urine samples from dogs with TCC/PCA that were treatment-naïve (n = 22) or receiving specific anticancer treatment at the time of sampling (n = 40), dogs with non-neoplastic diseases of the urinary tract (n = 22), dogs with other neoplasms (n = 35), dogs with a urinary tract infection (UTI; n = 45), and a group of healthy control dogs (n = 75) were used. The study design is summarized in the flow chart (Fig. 1). Cases were recruited at the Veterinary Medical Teaching Hospitals (VMTH) at Texas A&M University (n = 99), Michigan State University (n = 62) as part of another study [9], and three other North American universities (n = 40) as well as from seven Oncology referral practices located in five different US states (n = 38). Samples from some of the dogs (9 dogs with TCC/PCA, 9 dogs with a UTI, and 38 healthy dogs) had also been included in the assay validation study [34].
Fig. 1

Study flow chart summarizing the group distribution of the 239 dogs included into the study. The two different parts of the study are marked by the grey shaded areas: (i) evaluation of the urinary S100/calgranulins in dogs with a defined disease state; and (ii) evaluation of the diagnostic accuracy of the urinary S100/calgranulins for the diagnosis of transitional cell carcinoma (TCC)/prostatic carcinoma (PCA) in dogs ≥6 years of age (n = 141). #e.g., lack of a definitive diagnosis, not possible to categorize in one group (e.g., concurrent non-urinary tract malignancy and urinary tract infection), abnormal urinalysis results in healthy controls, or Leptospirosis suspect (analysis of urine considered as a possible public health concern)

Complete patient information was extracted from the electronic medical records (for all VMTH cases) or a study questionnaire that had to be completed by the owner and/or the attending veterinary oncologist prior to patient enrolment (for all referral practice cases).

Sample collection and analyses

Urine samples were obtained by cystocentesis, urethral catheterization, or free-catch, and were prepared for analysis of S100A8/A9 and S100A12 as previously described [34]. Briefly, debris was separated from samples by centrifugation for three minutes at 1000 × g, and the supernatants were placed into cryovials and stored frozen at −80 °C until analyses. Urine samples were then thawed and diluted 1:2 in 0.05 M sodium phosphate, 0.02% sodium azide, and 0.5% bovine serum albumin (pH 7.5) [34].

Urine S100A8/A9 and S100A12 were measured in all samples using established and validated species-specific in-house radioimmunoassays [34]. Urine concentrations of S100A8/A9 and S100A12 were normalized against urine specific gravity1 (S100A8/A9USG and S100A12USG), urine creatinine concentration2 (S100A8/A9Cre and S100A12Cre), and urine protein concentration3 (S100A8/A9Prot and S100A12Prot) [34]. In addition, the S100A8/A9-to-S100A12 ratio (uCalR) was calculated for each sample [34].

Data analyses

Commercial statistical software packages4 , 5 were used for all statistical analyses. Data were tested for the assumptions of normality and equality of variances using a Shapiro-Wilk and a Brown-Forsythe test, respectively. All parameters (S100A8/A9USG, S100A8/A9Cre, S100A8/A9Prot, S100A12USG, S100A12Cre, S100A12Prot, and uCalR) were tested among the six different groups of dogs using non-parametric multiple- (Kruskal-Wallis test followed by a Dunn’s test for multiple comparisons) or two-group (Mann-Whitney U test) comparisons. Summary statistics are reported as medians and interquartile ranges (IQR).

Receiver operating characteristic (ROC) curves were constructed to determine the sensitivities and specificities of normalized urinary S100A8/A9, S100A12, and the uCalR to distinguish dogs with TCC/PCA from the other groups of dogs; the Youden index was used to establish the optimum cut-off values. Positive (PPV) and negative predictive values (NPV) were calculated for the best-performing markers; the prior probability for a diagnosis of TCC/PCA in middle aged to older dogs (defined as ≥6 years of age) was estimated at 0.7% [2], and in dogs older than 6 years after exclusion of a UTI and those with clinical signs of lower urinary tract disease was estimated at 1% and 20%, respectively [8]. Significance was set at P < 0.05.

Results

Study population

Treatment-naïve TCC/PCA dogs

Breeds included Beagle (n = 3), Labrador Retriever (n = 3), Australian Cattle dog (n = 2), Scottish Terrier (n = 2), Shetland Sheepdog (n = 2), Australian Shepherd dog, Boston Terrier, Chow, Fox Terrier, Lhasa Apso (each n = 1), and mixed breed (n = 5). The most common tumor location was the urinary bladder (n = 15), followed by the urethra (n = 7), and the prostate (n = 5). The diagnosis was confirmed by histopathologic evaluation of a tissue biopsy (n = 7) or cytology (n = 15). A urine culture was performed in 12 dogs, 5 (42%) of which were positive for bacterial growth and the majority (80%) of positive samples were growing a single organism (E. coli, Enterococcus sp., Pseudomonas aeruginosa, or Streptococcus equisimilis).

TCC/PCA dogs under treatment

Breeds included Beagle (n = 5), Shetland Sheepdog (n = 4), West Highland White Terrier (n = 4), Scottish Terrier (n = 2), American Spitz, Bichon Frise, English Springer Spaniel, Jack Russell Terrier, Labrador Retriever, Maltese, Miniature Pinscher, Miniature Schnauzer, Papillion, Poodle, Rat Terrier, Schipperke (each n = 1), and mixed breed (n = 13). Most common tumor site was the urinary bladder (n = 33), followed by the prostate (n = 7), and the urethra (n = 6). Treatment at the time of urine sample collection included non-steroidal anti-inflammatory drugs (NSAID; piroxicam: n = 30; carprofen: n = 4; firocoxib: n = 2; deracoxib: n = 1), chemotherapy (mitoxantrone: n = 5; cyclophosphamide: n = 1), a tyrosine kinase inhibitor (toceranib phosphate: n = 3), and/or surgical excision (n = 2). The diagnosis had been previously confirmed by histopathology or cytology. A urine culture was performed in 7 dogs, 3 (43%) of which were positive for bacterial growth and a single organism (E. coli, Aerococcus sp., Mycoplasma canis) being isolated in the majority (80%) of the dogs that had a positive urine culture.

Dogs with UTI

Breeds included Beagle (n = 3), Boston Terrier (n = 3), Labrador Retriever (n = 3), Pug (n = 3), Standard Schnauzer (n = 3), Bichon Frise (n = 2), Brittany Spaniel (n = 2), Dachshund (n = 2), Golden Retriever (n = 2), Australian Cattle dog, Boxer, Cocker Spaniel, English Bulldog, Fox Terrier, French Bulldog, Great Dane, Husky, Jack Russell Terrier, Lhasa Apso, Miniature Poodle, Miniature Schnauzer, Pembroke Welsh Corgi, Rat Terrier, Rottweiler, Shih Tzu, Swiss Mountain dog (each n = 1), and mixed breed (n = 5). Urine culture was positive in 44/45 (98%) dogs, and marked bacteriuria but a negative culture was seen in one dog. The isolated bacterial strains were documented in 38 dogs, 6 (16%) of which had a polymicrobial UTI. The most common isolate was E. coli (n = 21), followed by Enterococcus sp. (n = 5), Klebsiella (n = 3), Proteus mirabilis (n = 6), Staphylococcus pseudintermedius (n = 2), Streptococcus canis (n = 2), Actinobacillus sp., Bacillus sp., Enterobacter sp., Pasteurella sp., Pseudomonas aeruginosa (each n = 1). A recurrent UTI was seen in one dog and a resistant UTI in two dogs. One dog had concurrent bilateral ureteral ectopy and one dog had urolithiasis.

Dogs with non-neoplastic urinary tract diseases

Breeds included Miniature Schnauzer (n = 3), Beagle (n = 2), Maltese (n = 2), Australian Shepherd, Bichon Frise, Bloodhound, Chihuahua, Dalmatian, Golden Retriever, Labrador Retriever, Miniature Poodle, Standard Schnauzer, Soft Coated Wheaten Terrier, Shih Tzu, West Highland White Terrier, Yorkshire Terrier (each n = 1), and mixed breed (n = 2). Diseases included urolithiasis (n = 11), International Renal Interest Society (IRIS) stage I-IV chronic kidney disease (n = 7), detrusor sphincter dyssynergia, polypoid cystitis, urethral stricture, or urethral sphincter mechanism incompetence (each n = 1).

Dogs with non-urinary tract neoplasia

Breeds included Beagle (n = 6), Labrador Retriever (n = 5), Shetland Sheepdog (n = 3), West Highland White Terrier (n = 3), Golden Retriever (n = 2), Scottish Terrier (n = 2), Basset Hound, Bearded Collie, Boxer, Brittany Spaniel, Cockapoo, German Shorthaired Pointer, Greater Swiss Mountain dog, Rottweiler (each n = 1), and mixed breed (n = 6). Neoplastic diseases were: lymphoma (n = 5), mast cell tumor (n = 5), hepatocellular carcinoma (n = 4), appendicular osteosarcoma (n = 3), undefined adrenal masses (n = 2), undefined splenic masses with hemoabdomen (n = 2), thymoma (n = 2), adrenal carcinoma, hemangiosarcoma, hepatic carcinoma, oral soft tissue sarcoma, oral squamous cell carcinoma, perianal adenoma, plasma cell tumor, pulmonary carcinoma, renal adenocarcinoma, undefined intracranial neoplasia, undefined mandibular neoplasia, and undefined mesenchymal neoplasia (each n = 1). Oncologic therapy at the time or prior to urine sample collection for the study included surgery (n = 12), chemotherapy (n = 8), and/or radiation therapy (n = 2).

Healthy control dogs

Breeds included West Highland White Terrier (n = 7), Beagle (n = 4), Labrador Retriever (n = 4), Dachshund (n = 3), Scottish Terrier (n = 3), Shetland Sheepdog (n = 3), American Pitbull Terrier (n = 2), Giant Schnauzer (n = 2), Miniature Schnauzer (n = 2), Weimaraner (n = 2), Yorkshire Terrier (n = 2), Australian Shepherd, Basset Hound, Bichon Frise, Border Collie, Boston Terrier, Boxer, Chihuahua, Chinese Shar Pei, English Springer Spaniel, French Bulldog, Golden Retriever, Great Dane, Neopolitan Mastiff, Portuguese Water dog, Saint Bernard, Standard Poodle, White Shepherd dog (each n = 1), and mixed breed (n = 17); breed was not documented in 7 dogs. Urinalysis was unremarkable in 64 dogs and was not performed on the same urinalysis in 11 dogs (these dogs were determined to be healthy based on previous diagnostics). Age-related conditions (e.g., degenerative joint disease) not reported to affect the urinary tract were not considered as an exclusion criterion.

Among group comparisons

Patient characteristics, urine S100A8/A9 and S100A12 concentrations, and the uCalR are summarized in Table 1. S100A8/A9USG (Fig. 2) and S100A8/A9Cre were numerically higher in dogs with untreated TCC/PCA than in dogs with TCC/PCA under treatment, but both differences did not reach significance (P = 0.2587 and 0.3715, respectively). No differences in S100A8/A9USG (Fig. 2) and S100A8/A9Cre were seen between treatment-naïve TCC/PCA dogs and those with a UTI (P = 0.1763 and 1.0000, respectively). Compared to treatment-naïve TCC/PCA dogs, urinary S100A12 concentrations were also lower in TCC/PCA dogs undergoing treatment, but the difference was only significant for S100A12Cre (P = 0.0416; P = 0.0664 for S100A12USG), whereas dogs with a UTI had numerically higher (but not significant) S100A12USG and S100A12Cre (both P = 1.0000).
Table 1

Patient characteristics, normalized urine S100A8/A9 and S100A12 concentrations, and the urine S100A8/A9-to-S100A12 ratio (uCalR) in all dogs included in the study (n = 239)

Parameter

TCC/PCA, treatment-naïve

TCC/PCA, under treatment

Bacterial urinary tract infection

Non-neoplastic UT disease

Other, non-UT neoplasia

Healthy control dogs

P value

Total number

22

40

45

22

35

75

Agec, in years median [IQR]

10.2 A [8.6–12.8]

11.1A [9.5–12.8]

8.8A [5.9–11.5]

10.0A [8.0–11.7]

9.4A [8.4–11.3]

5.5 B [3.0–8.8]

<0.0001

Weighta, in kg median [IQR]

18.2A [10.9–28.6]

13.7A [9.8–18.7]

12.7A [8.3–21.5]

9.8A [4.8–16.3]

21.8A [13.7–35.7]

18.1b, A [10.2–26.0]

0.0006

Sex

male/female

9/13

20/20

12/33

9/13

17/18

40/32b

0.0618

S100A8/A9USG c median [IQR]

438.5 A [199.8–8864.1]

196.3A [67.9–687.0]

310.7A [44.3–1384.5]

100.8 B [28.4–290.1]

23.5 B [13.4–97.6]

40.4 B [15.3–145.3]

<0.0001

S100A8/A9Cre c median [IQR]

933.6 A [353.8–11,600.2]

445.4A [145.5–1881.4]

956.3A [151.2–4242.0]

167.8 B [42.4–606.6]

53.3 B [29.6–225.7]

23.4 B [4.5–123.6]

<0.0001

S100A8/A9Prot c Median [IQR]

201.8 A [43.6–2541.9]

81.7A [36.1–259.0]

176.0A [33.5–637.3]

37.8 B [6.7–107.3]

16.4 B [5.0–66.7]

151.5A [69.7–699.7]

<0.0001

S100A12USG c median [IQR]

12.4 A [9.1–283.9]

5.0A [2.6–30.6]

44.5A [5.0–308.4]

2.8 B [1.7–16.8]

1.9 B [1.3–3.1]

4.5 B [3.0–7.6]

<0.0001

S100A12Cre c median [IQR]

35.2 A [14.7–803.6]

12.1 B [4.2–61.5]

176.3A [11.2–1323.1]

4.9 B [2.2–44.5]

3.9 B [2.7–6.6]

6.1 B [4.2–10.5]

<0.0001

S100A12Prot c median [IQR]

7.5 A [2.4–44.4]

3.0A [1.0–12.7]

41.3A [2.3–129.8]

2.4 B [0.5–6.7]

1.6 B [0.2–6.4]

10.9A [5.7–18.4]

<0.0001

uCalRc median [IQR]

14.7 A [10.6–37.7]

29.9A [7.5–71.1]

6.9 B [2.2–14.0]

14.2A [12.1–36.5]

12.1A [8.5–30.7]

10.6A [5.1–26.6]

<0.0001

TCC transitional cell carcinoma, PCA prostate gland carcinoma, UT urinary tract; ano significant differences detected when comparing individual groups with TCC/PCA group; bunknown in 3 dogs; cmedians [IQR in brackets] within a row not sharing a common superscript (boldface) are significantly different from treatment-naïve TCC/PCA dogs at P < 0.05. Global P value (boldface values indicate a significant difference at P < 0.05)

Fig. 2

Urinary concentrations of S100A8/A9 normalized against urine specific gravity (S100A8/A9USG) were significantly higher in newly diagnosed TCC/PCA dogs compared to dogs with non-neoplastic urinary tract (UT) diseases (P = 0.0088), dogs with neoplastic diseases not involving the urinary tract (P < 0.0001), and healthy control dogs (P < 0.0001); but did not differ from S100A8/A9USG measured in dogs with TCC/PCA undergoing cancer therapy (P = 0.2587) or dogs with a bacterial urinary tract infection (UTI; P = 0.1763). Boxes: interquartile range (IQR); vertical lines within boxes: medians; whiskers: determined by the outermost data points or values computed as (25th quartile – 1.5 × IQR) or (75th quartile +1.5 × IQR); dashed line: optimum cut-off concentration (≥109.9) to distinguish dogs with TCC/PCA from those of other groups; **significant difference at P < 0.01; ***significant difference at P < 0.001

The uCalR did not differ between newly diagnosed TCC/PCA dogs and those undergoing treatment (P = 1.0000), but the uCalR was significantly lower in dogs diagnosed with a UTI compared to all other disease groups of dogs: treatment-naïve TCC/PCA dogs (P = 0.0014) (Fig. 3), TCC/PCA dogs undergoing treatment (P < 0.0001), non-neoplastic urinary tract diseases (P = 0.0049), and neoplastic disease not involving the urinary tract (P = 0.0364).
Fig. 3

Urinary S100A8/A9-to-S100A12 ratios (uCalR) were significantly lower in dogs diagnosed with a urinary tract infection (UTI) compared to treatment-naïve TCC/PCA dogs (P = 0.0014), but did not differ between newly diagnosed TCC/PCA dogs and all other disease groups (all P = 1.0000) or healthy control dogs (P = 0.3030). Boxes: interquartile range (IQR); vertical lines within boxes: medians; whiskers: determined by the outermost data points or values computed as (25th quartile – 1.5 × IQR) or (75th quartile +1.5 × IQR); dashed line: optimum cut-off concentration (≥9.1) to distinguish dogs with TCC/PCA from dogs with a UTI; **significant difference at P < 0.01

S100A8/A9Prot and S100A12Prot were significantly higher in dogs with TCC/PCA than those with non-neoplastic urinary tract diseases (P = 0.0079 and 0.0485, respectively) or other neoplasms (P < 0.0001 and 0.0056, respectively) but were comparable to those in dogs with a UTI (both P = 1.0000) and healthy controls (both P = 1.0000).

Comparing urinary canine S100/calgranulin concentrations amongst the same groups of dogs after exclusion of all dogs <6 years of age yielded similar results, with the exception that the difference did not reach significance for S100A12USG in treatment-naïve TCC/PCA dogs compared to dogs with non-neoplastic urinary tract disease (P = 0.0574) and healthy control dogs (P = 0.0566), for S100A12Cre between treatment-naïve TCC/PCA dogs and those dogs with TCC/PCA under treatment (P= 0.1526), and for S100A12Prot between treatment-naïve TCC/PCA dogs and dogs with non-neoplastic urinary tract disease (P = 0.2245).

Within group comparisons

In patients with TCC/PCA, S100A8/A9USG, S100A8/A9Cre, S100A8/A9Prot, S100A12USG, S100A12Cre, S100A12Prot, and uCalR did not differ between dogs with a single tumor site (bladder, urethra, or prostate; n = 53) and dogs with more than one of those sites affected (n = 9; all P > 0.05). This finding was no different in treatment-naïve TCC/PCA dogs (all P > 0.05) and those dogs receiving antitumor therapy at the time of sample collection (all P > 0.05).

S100A8/A9Prot and S100A12Prot were significantly higher in treatment-naïve TCC/PCA dogs with a positive urine culture (n = 5; median [IQR]: 604.8 [392.9–10,353.6] and 39.8 [13.4–870.0], respectively) than dogs without a concurrent UTI (n = 7; median [IQR]: 44.5 [32.4–181.2] and 2.5 [1.1–6.1], respectively; both P = 0.0230), whereas no differences in S100A8/A9USG, S100A8/A9Cre, S100A12USG, S100A12Cre, or uCalR were seen between both groups of dogs (all P > 0.05).

S100A8/A9USG, S100A8/A9Cre, S100A8/A9Prot, S100A12USG, S100A12Cre, S100A12Prot, and uCalR did not differ among the three different primary tumor sites in newly diagnosed TCC/PCA dogs (all global P > 0.05), whereas S100A8/A9USG, S100A12USG, S100A12Cre, and S100A12Prot were significantly lower with primary involvement of the urinary bladder (n = 31; median [IQR]: 161.4 [67.3–361.5], 3.3 [2.3–13.5], 6.6 [3.6–32.9], and 2.0 [0.7–9.5], respectively) than the prostate (n = 7; median [IQR]: 1849.6 [563.1–5641.2], 239.6 [10.3–1274.4], 254.0 [18.9–2196.2], and 58.1 [9.2–119.0], respectively) in dogs undergoing treatment (P = 0.0274, 0.0020, 0.0128, and 0.0165, respectively). Also, S100A8/A9USG, S100A8/A9Cre, S100A8/A9Prot, S100A12USG, S100A12Cre, S100A12Prot, and uCalR did not differ between dogs treated with a single agent (n = 30) compared to combination protocols (n = 10; all P > 0.05) nor those treated with an NSAID (n = 37) compared to dogs not receiving an NSAID (n = 3; all P > 0.05).

In patients diagnosed with a UTI, S100A8/A9USG, S100A8/A9Cre, S100A8/A9Prot, S100A12USG, S100A12Cre, S100A12Prot, and uCalR did not differ in dogs with a single bacterial isolate (n = 43) from those with a polymicrobial UTI (n = 7; all P > 0.05); and there were no differences seen in dogs where only Enterococcus sp. (n = 5) and/or other isolates (n = 45) were cultured from urine samples (all P > 0.05).

Diagnostic accuracy

The area under the ROC curve (AUROC), optimum cut-off concentrations (and cut-off concentrations for at least a 90% sensitivity and a 90% specificity, respectively), sensitivities, and specificities are summarized in Table 2.
Table 2

Sensitivities and specificities at the optimal cut-off values (and cut-offs for resulting in a sensitivity and specificity of at least 90% each), and area under the receiver operating characteristic curve (AUROC) for urinary S100/calgranulins and the S100A8/A9-to-S100A12 ratio (uCalR) to distinguish treatment-naïve dogs with transitional cell carcinoma (TCC)/prostatic carcinoma (PCA) from other groups of dogs (all dogs ≥6 years of age [n = 141])

Parameter

AUROC

Cut-off

Sensitivity

Specificity

Treatment-naïve TCC/PCA (n = 22) vs. UTI (n = 35)

 S100A8/A9USG

0.671

≥96.3

96%

43%

≥8180.7

32%

94%

 S100A8/A9Cre

0.612

≥160.0

96%

35%

 S100A12USG

0.516

≤3.2

91%

29%

 S100A12Cre

0.521

≤117.9

68%

62%

 uCalR

0.751

≥9.1

91%

60%

≥5.2

100%

49%

≥72.2

18%

94%

Treatment-naïve TCC/PCA vs. other diseases causing lower urinary tract signs (n = 45)

 S100A8/A9USG

0.684

≥96.3

96%

44%

≥8230.7

32%

96%

 S100A8/A9Cre

0.631

≥167.8

96%

39%

 S100A12USG

0.548

≥7.0

82%

42%

 S100A12Cre

0.517

≥8.7

96%

34%

 uCalR

0.698

≥5.2

100%

40%

≥9.1

91%

49%

≥72.2

18%

96%

Treatment-naïve TCC/PCA vs. other disease groups (n = 86)a

 S100A8/A9USG

0.807

≥109.9

96%

64%

≥2274.8

36%

92%

 S100A8/A9Cre

0.763

≥188.9

96%

55%

≥8603.1

27%

91%

 S100A12USG

0.712

≥4.0

91%

57%

≥776.1

23%

93%

 S100A12Cre

0.697

≥8.7

96%

78%

≥2538.9

18%

95%

 uCalR

0.664

≥9.3

91%

42%

≥83.4

18%

96%

Treatment-naïve TCC/PCA vs. all other groups (n = 119)a

 S100A8/A9USG

0.824

≥109.9

96%

66%

≥2274.8

36%

93%

 S100A8/A9Cre

0.787

≥188.9

96%

59%

≥5783.2

36%

92%

 S100A12USG

0.740

≥7.0

82%

66%

≥221.0

27%

90%

 S100A12Cre

0.722

≥8.7

96%

57%

≥833.8

23%

90%

 uCalR

0.657

≥9.3

91%

41%

≥83.4

18%

96%

Treatment-naïve TCC/PCA vs. all other groups, excl. Urinary tract infections (n = 84)

 S100A8/A9USG

0.896

≥109.9

96%

75%

≥374.9

59%

95%

 S100A8/A9Cre

0.875

≥188.9

96%

70%

≥792.7

55%

91%

 S100A12USG

0.850

≥8.6

77%

86%

≥4.0

91%

71%

 S100A12Cre

0.838

≥10.7

91%

76%

≥92.3

32%

91%

 uCalR

0.612

≥9.3

91%

33%

aexcluding TCC/PCA dogs undergoing anticancer therapy

values in boldface are significant at P < 0.05

Using a uCalR of ≥9.3 or a S100A8/A9USG of ≥109.9 to screen middle-aged to older dogs (≥ 6 years of age) for TCC/PCA (0.7% estimated prevalence of TCC/PCA) yielded an NPV of 100% (1.000 for both) and a PPV between 1 and 2% (0.011 and 0.019, respectively). If a UTI has been excluded in the same population of dogs (estimated prevalence of TCC/PCA: 1%), a S100A8/A9USG ≥ 109.9 resulted in a NPV of ~100% (1.000) and a PPV of ~4% (0.038). In dogs ≥6 years of age, a uCalR of ≥5.2 [or ≥9.1] or a S100A8/A9USG of ≥96.3 differentiated patients with TCC/PCA from those with non-neoplastic causes of similar presenting signs (estimated prevalence of TCC/PCA in this population: 20%) with a NPV of 96–100% (1.000 [0.956] and 0.975, respectively) and a PPV of 29–31% (0.294 [0.308] and 0.301, respectively).

Use of a uCalR of ≥9.1 combined with a S100A8/A9USG of ≥109.9 to screen middle-aged to older dogs (≥ 6 years of age) for TCC/PCA (estimated prevalence: 0.7%) yielded a sensitivity of 86% (95% CI: 67–95%) and a specificity of 80% (95% CI: 72–87%; OR: 25.6, 95% CI: 7.3–88.5) (Fig. 4), with a NPV of ~100% (0.999; 95% Cl: 0.997–1.000) and a PPV of 3% (0.030; 95% CI: 0.020–0.044).
Fig. 4

Four-way Venn diagram demonstrating the separation between dogs with TCC/PCA (treatment-naïve) and all other groups of dogs ≥6 years of age by use of a uCalR ≥9.1 combined with a S100A8/A9USG ≥ 109.9

Discussion

This study evaluated the diagnostic utility of measuring urine concentrations of S100A8/A9 and S100A12 as well as the uCalR in dogs with TCC/PCA (treatment-naïve or undergoing antineoplastic therapy). Measurement of these biomarkers in urine specimens has the advantage of yielding information from the urinary tract. However, the results may be skewed by prerenal factors (e.g., increased amino acid turnover with neoplastic diseases causing glomerular hyperfiltration [35]), renal diseases (e.g., chronic kidney disease), and/or other diseases of the lower urinary tract (e.g., bacterial cystitis or urolithiasis). Thus, dogs with other non-neoplastic diseases of the urinary tract and dogs with neoplastic conditions not involving the urinary tract were included as disease control groups of dogs.

Diagnostic accuracy of the urinary canine S100/calgranulins was evaluated in dogs ≥6 years of age to mimic the situation of using these biomarkers in the clinical setting to screen for or diagnose dogs with TCC/PCA. The results of this study showed that urine S100A8/A9 and the uCalR may have limited diagnostic utility in dogs with TCC/PCA. Concentrations of urine S100A8/A9 as well as the parameters of diagnostic accuracy (AUROC, sensitivity, and specificity) and the optimum cut-offs for the separation of dogs diagnosed with TCC/PCA from the other groups of dogs were comparable to those in one study evaluating urine S100A8/A9 concentrations in humans with bladder cancer [30]. The study by Ebbing et al. also showed higher urine concentrations of S100A8/A9 in people with higher grade urothelial carcinomas [30]. However, the possibility of a correlation between urinary concentrations of the S100/calgranulins and the results of complete cancer staging and/or grading, response to treatment, and the individual patient outcome were not investigated as part of our study, and this will need to be further explored. Further research is also needed to determine when changes in S100A8/A9 and S100A12 could possibly occur along the spectrum of tumor development and whether these tests can detect pre-cancerous pathology or early cancer.

The components of diagnostic accuracy for the urinary S100/calgranulins in this study were higher than the sensitivity and specificity reported for urine sediment analysis, where neoplastic cells are detectable in approximately 30% of patients with TCC but neoplastic cells can be difficult to distinguish from reactive epithelial cells associated with inflammation [3, 5]. Also, both sensitivity and specificity of the S100A8/A9USG were higher than those of the V-BTA [69]. But similar to the V-BTA measurement, the S100A8/A9USG in dogs ≥6 years of age also suffers from a moderate rate of false positives (59% for dogs with a UTI and 24% [18–33%] for the remaining groups of dogs when using a cut-off of ≥109.9), which is also consistent with the increased urinary proteome fraction of S100A8/A9 and S100A12 (i.e., S100A8/A9Prot and S100A12Prot) in TCC/PCA dogs with concurrent UTI. An additional advantage over the V-BTA test [8], S100A8/A9USG is not affected by hematuria and offers a quantitative result [34].

The high sensitivity and NPV of S100A8/A9USG observed in this study suggest that measuring S100A8/A9USG could be a good screening test for TCC/PCA in dogs, especially patients where a UTI has been ruled out as a cause of clinical signs of lower urinary tract disease, and that a negative test result (i.e., a S100A8/A9USG of <109.9) essentially excludes a diagnosis of TCC/PCA in dogs. The uCalR, on the other hand, appears to be a better marker to distinguish patients with a UTI from those with TCC/PCA. However, the false negative rate of the uCalR in dogs ≥6 years old with a UTI was still moderate (54% and 43% when using ≥5.2 and ≥9.1 as the cut-off concentration, respectively), but a combination of S100A8/A9USG and the uCalR improved the diagnostic accuracy (i.e., specificity) for the detection of TCC/PCA in dogs. Similar to the V-BTA test [8], the PPV of the uCalR and S100A8/A9USG increased to about 30% if used in a population of dogs with a higher index of suspicion for lower urinary tract disease. Further prospective studies are warranted in a larger cohort of dogs to validate our findings and to directly compare the diagnostic performance of the urinary S100/calgranulins with the V-BTA test.

Dog breeds reported to have a higher risk of developing TCC (Scottish Terrier, West Highland White Terrier, Shetland Sheepdog, Beagle, and Dachshund) [13, 36] were overrepresented (36%) in our study. The female:male ratio (1.4:1) as well as the urinary bladder trigone being the most common tumor site were similar to previous reports [1, 3, 4, 8]. Detection of a concurrent UTI in 42% of the dogs with TCC/PCA (both treatment-naïve dogs and dogs undergoing anticancer therapy) and the spectrum of organisms isolated are also in line with the results of others [37].

An interesting finding of the current study is that, compared to dogs with TCC/PCA that received anticancer treatment at the time of urine sample collection, treatment-naïve dogs with TCC/PCA had 2.1- to 2.5-fold higher urinary S100A8/A9 concentrations and 2.5- to 2.9-fold higher urinary S100A12 concentrations (albeit statistical significance was reached only for S100A12Cre). While the cause of urinary S100/calgranulins being lower in dogs with TCC/PCA under treatment cannot be evaluated through this study, potential explanations include a decreased expression of these proteins by tumor cells or reduction of tumor-associated inflammation (particularly tumor-associated or even metastasis-associated macrophages) in response to treatment [38]. However, with the source and treatment-induced change of S100A8/A9 and S100A12 expression in canine TCC/PCA being unknown and the relatively large variation in the uCalR seen in the group of TCC/PCA dogs receiving anticancer treatment, it remains to be determined whether the S100/calgranulins are part of a pro-tumorigenic [39] or anti-tumorigenic [40] signature in canine TCC/PCA [38], or if they may even have a dual role. This distinction is particularly important as the synergism and convergence in the signaling pathways of inflammation and cancer – especially the release of damage-associated molecular pattern molecules (such as S100A8/A9 and S100A12), downstream activation of nuclear factor-κB, and expression of inflammatory cytokines and chemokines – can lead to positive feedback loops perpetuating chronic inflammation and thus a pro-tumorigenic microenvironment [13, 38].

From a clinical perspective, these aspects lend themselves to research of novel molecular-based therapeutic strategies aimed at targeting tumor-associated inflammation, which can drive tumor progression and metastasis [38, 41]. From a comparative oncology standpoint, study of the S100/calgranulins in canine TCC/PCA is of very high interest because here the spontaneous disease in dogs serves as a better model for human urothelial carcinoma than murine models (rodents lack S100A12 and S100A8 appears to functionally resemble S100A12 [4244]).

Another interesting finding in TCC/PCA dogs receiving anticancer therapy is that urinary S100A8/A9 and S100A12 concentrations were lower with primary involvement of the urinary bladder than that of the prostate. Whether this reflects a higher degree of tumor-associated inflammation with prostatic involvement, the response (increased antitumor immunity or treatment-induced inflammation) or even lack of response to treatment [38] requires further study. In view of this finding, the lack of a difference in urinary S100/calgranulin concentrations between TCC/PCA dogs given an NSAID (either alone or as part of a combination protocol) and those receiving other forms of antineoplastic therapy was unexpected as metronomic NSAIDs predominantly affect the tumor-promoting inflammation [1, 38] and the expression of S100A8 and S100A9 has been indirectly linked to the cyclooxygenase (COX)-2/cAMP pathway [45, 46].

We acknowledge the limitation of the study that healthy control dogs did not undergo the same diagnostic evaluation as patients with TCC/PCA or other urinary tract or non-urinary tract diseases. Thus, the possibility of an occult urinary tract disease (including TCC/PCA) cannot be excluded with certainty in this group of dogs.

Conclusions

The results of this study show that urine S100A8/A9 and the uCalR have utility as an exclusionary tool in dogs with suspected TCC/PCA. Despite a limited diagnostic value (i.e., as a confirmatory test), the high sensitivity and NPV of S100A8/A9USG suggests that S100A8/A9 could be a good screening test for TCC/PCA in dogs and that the uCalR can help differentiate dogs with a UTI. Further studies are warranted to validate our findings in a larger cohort of dogs, to evaluate the source of S100A8/A9 and S100A12 expression in canine TCC/PCA patients, and to determine whether S100A8/A9 and/or S100A12 expression correlates with tumor grade and/or complete tumor stage, response to treatment, progression of cancer, and/or survival time.

Footnotes
1

Clinical refractometer, Atago USA Inc., Bellevue, WA, USA.

 
2

Sirrus Creatinine LiquiColor, Stanbio Laboratory, Boerne, TX, USA.

 
3

Coomassie protein Bradford assay, Thermo Fisher Scientific Inc., Rockford, IL, USA.

 
4

Analyse-it® v4.20.1 Method validation edition, Analyse-it Software, Leeds, West Yorkshire, UK.

 
5

JMP® v12.0, SAS Institute Inc., Cary, NC, USA.

 

Abbreviations

AUROC: 

Area under the ROC curve

CI: 

Confidence interval

NPV: 

Negative predictive value

PCA: 

Prostatic carcinoma

PPV: 

Positive predictive value

ROC: 

Receiver operating characteristic curve

S100A12: 

S100A12 protein

S100A8/A9: 

S100A8/A9 (calprotectin) protein complex

TCC: 

Transitional cell carcinoma

uCalR: 

Urine S100A8/A9-to-S100A12 ratio

USG: 

Urine specific gravity

UTI: 

Urinary tract infection

Declarations

Acknowledgements

The authors acknowledge the help of Dr. Mary Nabity, Dr. Stephanie Smith, Dr. Tomomi Minamoto, Ms. Kelly Salgado, and Ms. Katja Weber with the collection and processing of urine samples.

Part of the data were presented at the 34rd Annual Meeting of the American College of Veterinary Internal Medicine (ACVIM), Denver, CO, USA (8–11 June, 2016).

Funding

This study was not supported by a grant or otherwise.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

RMH, EAM, NG, DJL, and JMS designed the study and enrolled patients into the study. RMH, NG, and DJL analysed the specimens from dogs enrolled in the study. RMH, EAM, NG, DJL, and JSS analysed and interpreted the patient and biomarker data. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval

The protocol for collection of urine samples from dogs with urinary tract disease and healthy dogs was independently reviewed and approved by the Clinical Research Review Committee at Texas A&M University (CRRC#2006–26 and #2010–43), and written consent was obtained from the owners of dogs enrolled in the study.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
College of Veterinary Medicine, University of Leipzig
(2)
Gastrointestinal Laboratory, Texas A&M University
(3)
Cummings School of Veterinary Medicine, Tufts University
(4)
College of Veterinary Medicine, Michigan State University
(5)
Farm Animal Clinic, Vetsuisse Faculty, University of Bern

References

  1. Mutsaers AJ, Widmer WR, Knapp DW. Canine transitional cell carcinoma. J Vet Intern Med. 2003;17(2):136–44.View ArticlePubMedGoogle Scholar
  2. Knapp DW, Ramos-Vara JA, Moore GE, et al. Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development. ILAR J. 2014;55(1):100–18.View ArticlePubMedGoogle Scholar
  3. Fulkerson CM, Knapp DW. Management of transitional cell carcinoma of the urinary bladder in dogs: a review. Vet J. 2015;205(2):217–25.View ArticlePubMedGoogle Scholar
  4. Knapp DW, Glickman NW, Denicola DB, et al. Naturally-occurring canine transitional cell carcinoma of the urinary bladder. A relevant model of human invasive bladder cancer. Urol Oncol. 2000;5(2):47–59.View ArticlePubMedGoogle Scholar
  5. Norris AM, Laing EJ, Valli VE, et al. Canine bladder and urethral tumors: a retrospective study of 115 cases (1980-1985). J Vet Intern Med. 1992;6(3):145–53.View ArticlePubMedGoogle Scholar
  6. Borjesson DL, Christopher MM, Ling GV. Detection of canine transitional cell carcinoma using a bladder tumor antigen urine dipstick test. Vet Clin Pathol. 1999;28(1):33–8.View ArticlePubMedGoogle Scholar
  7. Billet JP, Moore AH, Holt PE. Evaluation of a bladder tumor antigen test for the diagnosis of lower urinary tract malignancies in dogs. Am J Vet Res. 2002;63(3):370–3.View ArticlePubMedGoogle Scholar
  8. Henry CJ, Tyler JW, McEntee MC, et al. Evaluation of a bladder tumor antigen test as a screening test for transitional cell carcinoma of the lower urinary tract in dogs. Am J Vet Res. 2003;64(8):1017–20.View ArticlePubMedGoogle Scholar
  9. Sotirakopoulos AJ, Armstrong PJ, Heath L, et al. Evaluation of microsatellite instability in urine for the diagnosis of transitional cell carcinoma of the lower urinary tract in dogs. J Vet Intern Med. 2010;24(6):1445–51.View ArticlePubMedGoogle Scholar
  10. Allen DK, Waters DJ, Knapp DW, Kuczek T. High urine concentrations of basic fibroblast growth factor in dogs with bladder cancer. J Vet Intern Med. 1996;10(4):231–4.View ArticlePubMedGoogle Scholar
  11. Zhang J, Wei S, Liu L, et al. NMR-based metabolomics study of canine bladder cancer. Biochim Biophys Acta. 2012;1822(11):1807–14.View ArticlePubMedGoogle Scholar
  12. Bracha S, McNamara M, Hilgart I, et al. A multiplex biomarker approach for the diagnosis of transitional cell carcinoma from canine urine. Anal Biochem. 2014;455:41–7.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Foell D, Wittkowski H, Roth J. Mechanisms of disease: a ‘DAMP’ view of inflammatory arthritis. Nat Clin Pract Rheumatol. 2007;3(7):382–90.View ArticlePubMedGoogle Scholar
  14. Manolakis AC, Kapsoritakis AN, Tiaka EK, Potamianos SP. Calprotectin, calgranulin C, and other members of the S100 protein family in inflammatory bowel disease. Dig Dis Sci. 2011;56(6):1601–11.View ArticlePubMedGoogle Scholar
  15. Yao R, Lopez-Beltran A, Maclennan GT, et al. Expression of S100 protein family members in the pathogenesis of bladder tumors. Anticancer Res. 2007;27(5A):3051–8.PubMedGoogle Scholar
  16. Duan L, Wu R, Ye L, et al. S100A8 and S100A9 are associated with colorectal carcinoma progression and contribute to colorectal carcinoma cell survival and migration via Wnt/β-catenin pathway. PLoS One. 2013;8(4):e62092.View ArticlePubMedPubMed CentralGoogle Scholar
  17. De Ponti A, Wiechert L, Schneller D, et al. A pro-tumorigenic function of S100A8/A9 in carcinogen-induced hepatocellular carcinoma. Cancer Lett. 2015;369(2):396–404.View ArticlePubMedGoogle Scholar
  18. Zhang L, Jiang H, Xu G, et al. Proteins S100A8 and S100A9 are potential biomarkers for renal cell carcinoma in the early stages: results from a proteomic study integrated with bioinformatics analysis. Mol Med Rep. 2015;11(6):4093–100.PubMedPubMed CentralGoogle Scholar
  19. Hermani A, De Servi B, Medunjanin S, et al. S100A8 and S100A9 activate MAP kinase and NF-kB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res. 2006;312(2):184–97.View ArticlePubMedGoogle Scholar
  20. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol. 2006;8(12):1369–75.View ArticlePubMedGoogle Scholar
  21. Rafii S, Lyden D. S100 chemokines mediate bookmarking of premetastatic niches. Nat Cell Biol. 2006;8(12):1321–3.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Rehman I, Azzouzi AR, Catto JW, et al. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology. 2004;64(6):1238–43.View ArticlePubMedGoogle Scholar
  23. Hermani A, Hess J, De Servi B, et al. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res. 2005;11(14):5146–52.View ArticlePubMedGoogle Scholar
  24. Tolson JP, Flad T, Gnau V, et al. Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics. 2006;6(2):697–708.View ArticlePubMedGoogle Scholar
  25. Müller H, Haug U, Rothenbacher D, et al. Evaluation of serum and urinary myeloid related protein-14 as a marker for early detection of prostate cancer. J Urol. 2008;180(4):1309–12.View ArticlePubMedGoogle Scholar
  26. Ha YS, Kim MJ, Yoon HY, et al. mRNA expression of S100A8 as a prognostic marker for progression of non-muscle-invasive bladder cancer. Korean J Urol. 2010;51(1):15–20.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Kim SK, Kim EJ, Leem SH, et al. Identification of S100A8-correlated genes for prediction of disease progression in non-muscle invasive bladder cancer. BMC Cancer. 2010;10:21.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Kim WJ, Kim SK, Jeong P, et al. A four-gene signature predicts disease progression in muscle invasive bladder cancer. Mol Med. 2011;17(5–6):478–85.PubMedPubMed CentralGoogle Scholar
  29. Kim WT, Kim J, Yan C, et al. S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy. Ann Oncol. 2014;25(5):974–9.View ArticlePubMedGoogle Scholar
  30. Ebbing J, Mathia S, Seibert FS, et al. Urinary calprotectin: a new diagnostic marker in urothelial carcinoma of the bladder. World J Urol. 2014;32(6):1485–92.View ArticlePubMedGoogle Scholar
  31. Hsieh HL, Schäfer BW, Sasaki N, Heizmann CW. Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem Biophys Res Commun. 2003;307(2):375–81.View ArticlePubMedGoogle Scholar
  32. Khorramdelazad H, Bagheri V, Hassanshahi G, et al. S100A12 and RAGE expression in human bladder transitional cell carcinoma: a role for the ligand/RAGE axis in tumor progression? Asian Pac J Cancer Prev. 2015;16(7):2725–9.View ArticlePubMedGoogle Scholar
  33. Shapiro SG, Raghunath S, Williams C, et al. Canine urothelial carcinoma: genomically aberrant and comparatively relevant. Chromosom Res. 2015;23(2):311–31.View ArticleGoogle Scholar
  34. Heilmann RM, Wright ZM, Lanerie DJ, et al. Measurement of urinary canine S100A8/A9 and S100A12 concentrations as candidate biomarkers of lower urinary tract neoplasia in dogs. J Vet Diagn Investig. 2014;26(1):104–12.View ArticleGoogle Scholar
  35. Hjorth L, Wiebe T, Karpman D. Hyperfiltration evaluated by glomerular filtration rate at diagnosis in children with cancer. Pediatr Blood Cancer. 2011;56(5):762–6.View ArticlePubMedGoogle Scholar
  36. Davis BW, Ostrander EA. Domestic dogs and cancer research: a breed-based genomics approach. ILAR J. 2014;55(1):59–68.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Budreckis DM, Byrne BA, Pollard RE, et al. Bacterial urinary tract infections associated with transitional cell carcinoma in dogs. J Vet Intern Med. 2015;29(3):828–33.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Raposo TP, Beirão BC, Pang LY, et al. Inflammation and cancer: till death tears them apart. Vet J. 2015;205(2):161–74.View ArticlePubMedGoogle Scholar
  39. Turovskaya O, Foell D, Sinha P, et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis. 2008;29(10):2035–43.View ArticlePubMedPubMed CentralGoogle Scholar
  40. Ehrchen JM, Sunderkötter C, Foell D, et al. The endogenous toll-like receptor 4 agonist S100A8/A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009;86(3):557–66.View ArticlePubMedGoogle Scholar
  41. Hanada T, Nakagawa M, Emoto A, et al. Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol. 2000;7(7):263–9.View ArticlePubMedGoogle Scholar
  42. Foell D, Frosch M, Sorg C, Roth J. Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta. 2004;344(1–2):37–51.View ArticlePubMedGoogle Scholar
  43. Fuellen G, Nacken W, Sorg C, Kerkhoff C. Computational searches for missing orthologs: the case of S100A12 in mice. OMICS. 2004;8(4):334–40.View ArticlePubMedGoogle Scholar
  44. Hsu K, Champaiboon C, Guenther BD, et al. Anti-infective protective properties of S100 calgranulins. Antiinflamm Antiallergy Agents Med Chem. 2009;8(4):290–305.View ArticlePubMedPubMed CentralGoogle Scholar
  45. Hsu K, Passey RJ, Endoh Y, et al. Regulation of S100A8 by glucocorticoids. J Immunol. 2005;174(4):2318–26.View ArticlePubMedGoogle Scholar
  46. Xu K, Yen T, Geczy CL. IL-10 up-regulates macrophage expression of the S100 protein S100A8. J Immunol. 2001;166(10):6358–66.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017